vs
Broadstone Net Lease, Inc.（BNL）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是Broadstone Net Lease, Inc.的1.0倍（$127.1M vs $121.4M），再鼎医药同比增速更快（17.1% vs 11.7%），过去两年再鼎医药的营收复合增速更高（20.8% vs 7.1%）
Broadstone Net Lease, Inc.是一家房地产投资信托公司，主要在美国市场收购、持有并管理单一租户商业地产资产组合，覆盖工业设施、医疗物业、零售门店、办公空间等核心板块，所有物业均与租户签订长期净租赁协议。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
BNL vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.0倍
$121.4M
营收增速更快
ZLAB
高出5.4%
11.7%
两年增速更快
ZLAB
近两年复合增速
7.1%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $121.4M | $127.1M |
| 净利润 | $46.4M | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | 52.2% | -54.6% |
| 净利率 | 38.2% | — |
| 营收同比 | 11.7% | 17.1% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $0.24 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BNLZLAB
| Q1 26 | $121.4M | — | ||
| Q4 25 | $118.3M | $127.1M | ||
| Q3 25 | $114.2M | $115.4M | ||
| Q2 25 | $113.0M | $109.1M | ||
| Q1 25 | $108.7M | $105.7M | ||
| Q4 24 | $112.1M | $108.5M | ||
| Q3 24 | $108.4M | $101.8M | ||
| Q2 24 | $105.9M | $100.1M |
净利润BNLZLAB
| Q1 26 | $46.4M | — | ||
| Q4 25 | $33.1M | — | ||
| Q3 25 | $26.5M | $-36.0M | ||
| Q2 25 | $20.2M | $-40.7M | ||
| Q1 25 | $16.7M | $-48.4M | ||
| Q4 24 | $26.4M | — | ||
| Q3 24 | $35.6M | $-41.7M | ||
| Q2 24 | $35.3M | $-80.3M |
毛利率BNLZLAB
| Q1 26 | — | — | ||
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% |
营业利润率BNLZLAB
| Q1 26 | 52.2% | — | ||
| Q4 25 | — | -54.6% | ||
| Q3 25 | — | -42.3% | ||
| Q2 25 | — | -50.3% | ||
| Q1 25 | — | -53.3% | ||
| Q4 24 | — | -62.6% | ||
| Q3 24 | — | -66.6% | ||
| Q2 24 | — | -76.0% |
净利率BNLZLAB
| Q1 26 | 38.2% | — | ||
| Q4 25 | 28.0% | — | ||
| Q3 25 | 23.2% | -31.2% | ||
| Q2 25 | 17.8% | -37.3% | ||
| Q1 25 | 15.4% | -45.8% | ||
| Q4 24 | 23.5% | — | ||
| Q3 24 | 32.8% | -40.9% | ||
| Q2 24 | 33.4% | -80.2% |
每股收益（稀释后）BNLZLAB
| Q1 26 | $0.24 | — | ||
| Q4 25 | $0.17 | $-0.05 | ||
| Q3 25 | $0.14 | $-0.03 | ||
| Q2 25 | $0.10 | $-0.04 | ||
| Q1 25 | $0.09 | $-0.04 | ||
| Q4 24 | $0.13 | $-0.09 | ||
| Q3 24 | $0.19 | $-0.04 | ||
| Q2 24 | $0.19 | $-0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $20.3M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $3.0B | $715.5M |
| 总资产 | $5.8B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BNLZLAB
| Q1 26 | $20.3M | — | ||
| Q4 25 | $30.5M | $689.6M | ||
| Q3 25 | $82.0M | $717.2M | ||
| Q2 25 | $20.8M | $732.2M | ||
| Q1 25 | $9.6M | $757.3M | ||
| Q4 24 | $14.8M | $779.7M | ||
| Q3 24 | $9.0M | $616.1M | ||
| Q2 24 | $18.3M | $630.0M |
总债务BNLZLAB
| Q1 26 | — | — | ||
| Q4 25 | $2.5B | — | ||
| Q3 25 | $2.4B | — | ||
| Q2 25 | $2.1B | — | ||
| Q1 25 | $2.0B | — | ||
| Q4 24 | $1.9B | — | ||
| Q3 24 | $2.0B | — | ||
| Q2 24 | $1.9B | — |
股东权益BNLZLAB
| Q1 26 | $3.0B | — | ||
| Q4 25 | $2.9B | $715.5M | ||
| Q3 25 | $2.9B | $759.9M | ||
| Q2 25 | $2.9B | $791.7M | ||
| Q1 25 | $2.9B | $810.8M | ||
| Q4 24 | $3.0B | $840.9M | ||
| Q3 24 | $3.0B | $667.7M | ||
| Q2 24 | $3.1B | $704.2M |
总资产BNLZLAB
| Q1 26 | $5.8B | — | ||
| Q4 25 | $5.7B | $1.2B | ||
| Q3 25 | $5.5B | $1.2B | ||
| Q2 25 | $5.3B | $1.2B | ||
| Q1 25 | $5.2B | $1.2B | ||
| Q4 24 | $5.2B | $1.2B | ||
| Q3 24 | $5.3B | $985.3M | ||
| Q2 24 | $5.3B | $987.4M |
负债/权益比BNLZLAB
| Q1 26 | — | — | ||
| Q4 25 | 0.87× | — | ||
| Q3 25 | 0.82× | — | ||
| Q2 25 | 0.73× | — | ||
| Q1 25 | 0.68× | — | ||
| Q4 24 | 0.64× | — | ||
| Q3 24 | 0.65× | — | ||
| Q2 24 | 0.62× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | — | $-26.7M |
| 自由现金流率自由现金流/营收 | — | -21.0% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-158.9M |
8季度趋势，按日历期对齐
经营现金流BNLZLAB
| Q1 26 | — | — | ||
| Q4 25 | $299.5M | $-26.0M | ||
| Q3 25 | $64.2M | $-32.0M | ||
| Q2 25 | $79.3M | $-31.0M | ||
| Q1 25 | $71.5M | $-61.7M | ||
| Q4 24 | $276.3M | $-55.8M | ||
| Q3 24 | $67.3M | $-26.8M | ||
| Q2 24 | $74.2M | $-42.2M |
自由现金流BNLZLAB
| Q1 26 | — | — | ||
| Q4 25 | $269.8M | $-26.7M | ||
| Q3 25 | $58.0M | $-35.0M | ||
| Q2 25 | $76.7M | $-33.9M | ||
| Q1 25 | $57.1M | $-63.2M | ||
| Q4 24 | $259.5M | $-58.4M | ||
| Q3 24 | $60.3M | $-28.2M | ||
| Q2 24 | $74.0M | $-42.9M |
自由现金流率BNLZLAB
| Q1 26 | — | — | ||
| Q4 25 | 228.1% | -21.0% | ||
| Q3 25 | 50.8% | -30.4% | ||
| Q2 25 | 67.9% | -31.1% | ||
| Q1 25 | 52.5% | -59.9% | ||
| Q4 24 | 231.4% | -53.8% | ||
| Q3 24 | 55.6% | -27.7% | ||
| Q2 24 | 69.9% | -42.9% |
资本支出强度BNLZLAB
| Q1 26 | — | — | ||
| Q4 25 | 25.1% | 0.5% | ||
| Q3 25 | 5.4% | 2.6% | ||
| Q2 25 | 2.3% | 2.6% | ||
| Q1 25 | 13.2% | 1.5% | ||
| Q4 24 | 15.0% | 2.4% | ||
| Q3 24 | 6.5% | 1.3% | ||
| Q2 24 | 0.2% | 0.7% |
现金转化率BNLZLAB
| Q1 26 | — | — | ||
| Q4 25 | 9.04× | — | ||
| Q3 25 | 2.43× | — | ||
| Q2 25 | 3.93× | — | ||
| Q1 25 | 4.27× | — | ||
| Q4 24 | 10.47× | — | ||
| Q3 24 | 1.89× | — | ||
| Q2 24 | 2.10× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BNL
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
